

Model-free estimation of driver interactions across cancers


Yuelin Yao^{1, 2}, Abel Jansma^{2, 3}, Luigi Del Debbio³, Sjoerd Beentjes^{2, 4}, Chris Ponting², Ava Khamseh^{1, 2, 3}

¹School of Informatics, University of Edinburgh, Edinburgh EH8 9AB, United Kingdom.

²MRC Human Genetics Unit, Institute of Genetics & Cancer, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom.

³Higgs Centre for Theoretical Physics, School of Physics Astronomy, University of Edinburgh, Edinburgh EH9 3FD, United Kingdom.

⁴School of Mathematics, University of Edinburgh Edinburgh EH9 3JZ, United Kingdom.



THE UNIVERSITY
of EDINBURGH




1 Motivation

- Large-scale cancer genomics programs (e.g., TCGA, ICGC) have provided an unprecedented opportunity to identify cancer driver genes and mutations.
- A single driver mutation or a single driver gene is usually not sufficient to induce oncogenesis, and how genetic interactions contribute to cancer phenotypes is still under investigation.
- To date, most cancer studies have mainly reported pairwise interactions at the gene level, and neglected the interactions at the mutation level.
- The lack of data on higher-order interactions should not be misunderstood as a proof that higher-order interactions do not exist or are less important.

2 Graphical summary

We apply a model-independent approach to estimate pairwise and higher-order interactions at both gene and site levels. Using data from **34,674** tumour samples across **24** cancer types, we are able to identify key interactions within and across cancer types, accounting for co-occurrence, mutual exclusivity as well as more complex higher-order relationships.



3 Model-free interactions


Definition

Let X be the mutational status of a set of driver genes or mutation sites (0, not mutated; 1, mutated). A pair of driver genes or mutations $\{X_i, X_j\} \in X$ has a pairwise interaction I_{ij} , where:

$$I_{ij} = \log \frac{p(X_i = 1, X_j = 1 | \underline{X} = 0) p(X_i = 0, X_j = 0 | \underline{X} = 0)}{p(X_i = 1, X_j = 0 | \underline{X} = 0) p(X_i = 0, X_j = 1 | \underline{X} = 0)}$$


- It is **model-independent** and can be directly estimated from observations [1].
- Condition on the **Markov boundary**, a minimal subset conditioned on which X_i and X_j become independent of other mutations.
- Markov boundary is identified by **iterative MCMC** method for causal discovery [2].
- Standard deviation is computed using **bootstrap resampling**.
- If two mutations or genes are independent, $I_{ij}=0$.
- It can be extended to **higher-order interaction** by taking n 'th derivatives of $\log p(X)$:

$$I_{ijk} = \log \frac{p(1, 1, X_k | \underline{X}) p(0, 0, X_k | \underline{X})}{p(0, 1, X_k | \underline{X}) p(0, 1, X_k | \underline{X})} \\ = \log \left(\frac{p(1, 1, 1 | \underline{X}) p(0, 0, 1 | \underline{X}) p(0, 1, 0 | \underline{X}) p(1, 0, 0 | \underline{X})}{p(0, 0, 0 | \underline{X}) p(0, 1, 1 | \underline{X}) p(1, 1, 0 | \underline{X}) p(1, 0, 1 | \underline{X})} \right)$$



Interpretation

- **Positive pairwise interaction**: pairs of mutated genes or mutations are more likely to co-occur than being mutually exclusive in cancer population, indicative of two **collaborating oncogenic pathways** of hallmark features [3].
- **Negative pairwise interaction**: pairs of mutated genes or mutations are more likely to be mutually exclusive than being co-occurring, which might point to **synthetic lethal** or **synthetic essentiality** [3].



Schematic representation of pairwise genetic interactions


- **Three-point interaction**: mutations in a third gene affect the genetic interaction between the other two genes.

4 Interactions reveal underlying biology

Genetic interactions are context-dependent

- Genetic interactions are highly **cancer-type specific**.
- The sign of pairwise interaction might change across tissues, e.g., **PIK3CA** vs. **KRAS**, negative in lung cancer, but positive in large intestine cancer.
- The sign might also change depending on the aggregation approach or whether it is gene level or mutation level, e.g., in CNS cancer, **IDH1 R132H** mutation particularly selects for **TP53 R273C** mutation, compared to other **TP53** mutations.
- Higher-order interactions exist, e.g., **TP53, ATRX, IDH1** in CNS cancer.

Functionally relevant mechanisms of oncogenic pathways



5 Conclusion

Overall, these key interactions reflect the perturbation of cancer-relevant pathways or processes and might provide great benefits including:

- Gaining common mechanistic insights into the progression of cancer.
- Identifying prognostic or predictive interactions.
- Uncovering potential targeted and combination therapeutic opportunities.
- Stratifying tumour subtypes based on interactions.

References

1. Beentjes, S. & Khamseh, A. Higher-order interactions in statistical physics and machine learning: A model-independent solution to the inverse problem at equilibrium. *Physical Review E* **102**, 053314 (2020).
2. Kuipers, J. et al. Efficient sampling and structure learning of Bayesian networks. *Journal of Computational and Graphical Statistics*, 1–12 (2022).
3. El Tekle, G. et al. Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. *Trends in cancer* **7**, 823–836 (2021).